Tag Archives: cra

DBruggeman

CRA President among life science's most inspiring

Tempe-based Clinical Research Advantage (CRA), the country’s largest wholly owned network of clinical trial sites, announced that the company’s President & Chief Operating Officer,  David M. Bruggeman, has been selected by PharmaVOICE Magazine as one of the 100 most inspiring people in the life sciences industry. Bruggeman, a 30-year healthcare industry veteran, was honored for his vision and innovation in the clinical trials industry.

Since acquiring CRA in 2007, Bruggeman has been the pioneering force behind the development of an integrated platform for clinical research. This platform has allowed CRA to standardize its research procedures and make the trial process safer and more efficient. It has also enabled CRA to expand rapidly – growing from just six sites in Phoenix to more than 60 sites across the country in the past six years.

“David is an inspiring leader who is dedicated to furthering our industry,” said Mark S. Hanley, CRA’s Chief Executive Officer.  “David’s work has improved the quality and efficiency of clinical trials and improved the patient experience. On behalf of the CRA team, I’d like to congratulate David on this well-deserved honor.”

The PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. Nominated by thousands of PharmaVOICE readers, the recipients are selected based on comprehensive essays describing how they have inspired or motivated their colleagues, peers and others; and how they have affected positive change in their organizations or communities. The individuals of the PharmaVOICE 100 represent a broad cross section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, technology and many others.

DBruggeman

CRA President among life science’s most inspiring

Tempe-based Clinical Research Advantage (CRA), the country’s largest wholly owned network of clinical trial sites, announced that the company’s President & Chief Operating Officer,  David M. Bruggeman, has been selected by PharmaVOICE Magazine as one of the 100 most inspiring people in the life sciences industry. Bruggeman, a 30-year healthcare industry veteran, was honored for his vision and innovation in the clinical trials industry.

Since acquiring CRA in 2007, Bruggeman has been the pioneering force behind the development of an integrated platform for clinical research. This platform has allowed CRA to standardize its research procedures and make the trial process safer and more efficient. It has also enabled CRA to expand rapidly – growing from just six sites in Phoenix to more than 60 sites across the country in the past six years.

“David is an inspiring leader who is dedicated to furthering our industry,” said Mark S. Hanley, CRA’s Chief Executive Officer.  “David’s work has improved the quality and efficiency of clinical trials and improved the patient experience. On behalf of the CRA team, I’d like to congratulate David on this well-deserved honor.”

The PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. Nominated by thousands of PharmaVOICE readers, the recipients are selected based on comprehensive essays describing how they have inspired or motivated their colleagues, peers and others; and how they have affected positive change in their organizations or communities. The individuals of the PharmaVOICE 100 represent a broad cross section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, technology and many others.

medical.research

Clinical Research Advantage expands reach

Clinical Research Advantage (CRA), the country’s largest wholly owned network of clinical trial sites, has further expanded its geographic and therapeutic reach by acquiring the late phase division of Comprehensive Clinical Development (CCD). This transaction will allow CRA to offer pharmaceutical sponsors and contract research organizations an across-the-board solution for their diverse clinical research needs.

Clinical Research Advantage includes 63 sites listed under “CRA” and “Radiant Research.” Both brands are known as leaders in Stage II-IV clinical trials. CRA focuses on on family practice and general medicine, while Radiant conducts multi-specialty and consumer trials. Comprehensive Clinical Development is a leader in psychiatric clinical trials, specifically in the areas of schizophrenia, bipolar disorder, depression, and Alzheimer’s disease. CCD has participated in the development of every major psychiatric drug that has been developed over the past 10 years, and it is recognized in the industry as a high quality researcher and successful enroller for psychiatric trials.

“By adding Comprehensive Clinical Development to the CRA family of trial sites we are able to increase our capabilities to meet the needs of the growing pharmaceutical marketplace,” said Mark S. Hanley, Chief Executive Officer of CRA. “We are excited about this partnership and the opportunity to move into new therapeutic areas of clinical research. CCD has an impressive track record in psychiatric trials, and we see it as an ideal partner as we continue to expand our operations.”

Based in Miramar, Fla., CCD was founded in 1998. The company operates four independent sites in Atlanta, Ga., Cerritos, Calif., Holliswood, N.Y., and Washington, D.C. The combined companies will continue to function under the names Clinical Research Advantage and Comprehensive Clinical Development, but will be looking to integrate and streamline their operations where appropriate.

Mark H pics 012

CRA’s CEO Wins Gold Stevie Award

Mark S. Hanley, Chief Executive Officer of Clinical Research Advantage, Inc. (CRA), was the recipient of a Gold Stevie® Award in this year’s American Business Awards. Hanley was recognized as the “Maverick of the Year” in the Business Services category.

Hanley was honored for his innovative vision and leadership, which included acquiring Radiant Research in 2012 to create the country’s largest and most therapeutically diverse integrated network of clinical trial sites. “It is an honor to receive this award,” said Hanley. “But, this is really an award for the entire CRA team. It is through all of their hard work and dedication that we have accomplished so much in the past 12 months.”

The American Business Awards are the nation’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.

Nicknamed the Stevies for the Greek word for “crowned,” the 11th annual award ceremony was held on June 17th in Chicago, Illinois. This year, the judges reviewed more than 3,200 nominations from organizations of all sizes and virtually every industry.

 

Mark H pics 012

CRA's CEO Wins Gold Stevie Award

Mark S. Hanley, Chief Executive Officer of Clinical Research Advantage, Inc. (CRA), was the recipient of a Gold Stevie® Award in this year’s American Business Awards. Hanley was recognized as the “Maverick of the Year” in the Business Services category.

Hanley was honored for his innovative vision and leadership, which included acquiring Radiant Research in 2012 to create the country’s largest and most therapeutically diverse integrated network of clinical trial sites. “It is an honor to receive this award,” said Hanley. “But, this is really an award for the entire CRA team. It is through all of their hard work and dedication that we have accomplished so much in the past 12 months.”

The American Business Awards are the nation’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.

Nicknamed the Stevies for the Greek word for “crowned,” the 11th annual award ceremony was held on June 17th in Chicago, Illinois. This year, the judges reviewed more than 3,200 nominations from organizations of all sizes and virtually every industry.

 

DBruggeman

CRA President Receives Stevie Awards

David M. Bruggeman, President and Chief Operating Officer of Clinical Research Advantage, Inc. (CRA), was the recipient of two Stevie Awards at the 11th annual American Business Awards. Bruggeman received the Bronze Award for “Executive of the Year” in both the Pharmaceuticals and Health Products and Services categories.

Bruggeman was recognized for his ingenuity and leadership in building the country’s largest integrated network of clinical trial sites and partnering with Quintiles to create the first-ever therapeutic alliance for clinical trials in primary medicine. “David is an extraordinary leader whose work has improved the quality and efficiency of the clinical research process,” said Mark S. Hanley, CRA’s Chief Executive Officer. “We are happy to hear that David has received this national honor.”

The American Business Awards are the nation’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.

Nicknamed the Stevies for the Greek word for “crowned,” the awards were held on June 17th in Chicago, Illinois. This year, the judges reviewed more than 3,200 nominations from organizations of all sizes and virtually every industry.

Vesely

CRA Finance Department earns honors

Clinical Research Advantage’s Finance Department received two national honors in this year’s Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts. The company received the Silver Award for Finance Executive of the Year and Finance Department of the Year.

Jim Vesely, Chief Financial Officer, and his team of Sandy Zipp, Accountant, and Jan Jacobson, Accounting Associate, were recognized for developing and implementing a metrics system that allowed the company to increase revenue and obtain the capital needed for expansion. CRA experienced rapid growth in 2011 and 2012, becoming largest and most therapeutically diverse integrated site network in the clinical trials industry.

“Jim Vesely and his team have done an extraordinary job. Through their efforts, CRA was able to grow our geographic presence and our employee base at a time when many other businesses in our industry were cutting back,” said Mark S. Hanley, CRA’s Chief Executive Officer. “The awards received by Jim, Sandy and Jan are well deserved.”

More than 400 entries were received in this year’s awards program, from a wide array of public and private companies of all sizes and from a variety of industries and regions in the U.S. and Canada.

Winners of Best in Biz Awards 2012 were determined by an independent panel of 32 judges from top-tier news, business and technology publications, as well as broadcast outlets and analyst firms, such as ABC, Businessweek, Computerworld, ECT News Network, Entrepreneur, eWeek, Examiner, Financial Times, Forbes, FOX News, Hartford Business Journal, IDG Ventures, IEEE Institute, Inc., Insight Media, King Features Syndicate, Lab Reviews, Network World, The News and Observer, PC Magazine, ReadWriteWeb, South Florida Business Journal, Tech-Gaming, Techtalk, Upstart Business Journal, USA Today and ZDNet.

Orvin & Drake

CRA Receives Gold Best in Biz Award

Clinical Research Advantage (CRA) received top honors in this year’s Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts. CRA received the Gold Award for Business Development Department of the Year.

Casey Orvin, Vice President of Business Development, and Amanda Drake, Director of Business Development, were recognized for their achievements in helping the company grow to become the largest and most therapeutically diverse integrated site network in the clinical trials industry.

“Casey Orvin and Amanda Drake have been vital to CRA’s substantial growth over the past couple of years,” said Mark S. Hanley, the company’s Chief Executive Officer. “Through their efforts, the number of clinical trials conducted by CRA increased by nearly 150%, and it continues to grow at an unprecedented rate.”

More than 400 entries were received in this year’s awards program, from a wide array of public and private companies of all sizes and from a variety of industries and regions in the U.S. and Canada.

Winners of Best in Biz Awards 2012 were determined by an independent panel of 32 judges from top-tier news, business and technology publications, as well as broadcast outlets and analyst firms, such as ABC, Businessweek, Computerworld, ECT News Network, Entrepreneur, eWeek, Examiner, Financial Times, Forbes, FOX News, Hartford Business Journal, IDG Ventures, IEEE Institute, Inc., Insight Media, King Features Syndicate, Lab Reviews, Network World, The News and Observer, PC Magazine, ReadWriteWeb, South Florida Business Journal, Tech-Gaming, Techtalk, Upstart Business Journal, USA Today and ZDNet.

Mark H pics 001

CRA forms alliance with Quintiles

Tempe-based Clinical Research Advantage (CRA), the country’s largest community-based network of clinical trial sites, has entered into a strategic agreement  with Quintiles to facilitate a higher level of clinical trial participation with an emphasis on safety, improved study efficiencies and excellent quality data in medical research. Clinical Research Advantage is the first therapeutically aligned network of Family Medicine community-based sites selected by Quintiles as a strategic alliance.

“It is an honor to be chosen by Quintiles, the world’s largest biopharmaceutical services provider with the highest standards for quality and safety,” said Mark S. Hanley, CRA’s Chief Executive Officer. “The core value and principal purpose of Clinical Research Advantage is to improve the lives of patients through the development of new medical therapies. Working with Quintiles will allow CRA to conduct an increased number of community-based trials with unparalleled accuracy and safety.”

“Clinical Research Advantage impressed us with their high standards for quality, high patient enrolments, and exceptional study start-up abilities,” said Lindy Jones, Senior Vice President, Integrated Site Services, Quintiles. “Many chronic conditions such as diabetes and heart disease are now managed in the community. It is imperative that these patient populations have the opportunity to participate in studies and be a part of the quest to develop new and better medicines for conditions that have a significant impact on both individuals and society.  We are pleased to enter into this relationship with CRA and anticipate that together we will ensure that studies start on the right path.”

The CRA-Quintiles relationship marks a new era in Phase II – IV clinical trials, enabling physicians and clinical researchers to conduct an increased number of trials across a wide range of disease areas. In addition, it will streamline and expedite the process of bringing these potentially life-changing and life-saving drugs to market.
About Clinical Research Advantage

Tempe, Arizona-based Clinical Research Advantage, Inc. (CRA) is a provider of a range of research services to pharmaceutical companies and clinical research organizations. As a leading trial management organization, CRA operates from 38 sites across 17 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and efficiently. Founded in 1992, CRA has successfully completed more than 1,800 clinical trials on behalf of its clients. For more information, please visit www.crastudies.com.

medical.research

Tempe’s CRA acquires Radiant Research

Tempe-based CRA Holdings, LLC announced that it has acquired Radiant Research, Inc. CRA Holdings is the company that also owns Clinical Research Advantage (CRA), another major player in the SMO market. By combining these two entities under the same investment portfolio, the organizations collectively have 57 sites with more than 550 research professionals and an aggressive plan for growth.

Over the past 15 years, Radiant Research has focused on common and chronic conditions that can be recruited from the general population. Radiant specializes in trials that require large numbers of subjects to be recruited in a short period of time, or complex trials that require specialized equipment or procedures. Radiant has large stand-alone facilities in which it conducts research; the company recruits studies primarily from an active database of over one million volunteers. CRA, on the other hand, is a practice-based organization, where 85% or greater of trial participants are recruited from the investigator’s private practice. This has allowed CRA to focus on trials where disease-state management is required. Both organizations are leaders in vaccine trial execution. The union of these two companies provides for better access to patients, an ability to conduct a diverse array of trials and broader geographic diversity.

“The Radiant platform will facilitate faster expansion of our model by utilizing the Radiant sites to help launch practice-based satellite locations in the cities where Radiant already has sites. We have grown CRA from seven to 37 sites in the last five years. In order for us to achieve our goal of 80 or 90 sites in the manner we have been doing would take us at least another five years.  The Radiant acquisition will be the catalyst for much faster growth in the next 12 months,” said Mark Hanley, CEO of CRA.

“By combining the models under one umbrella, we will be able to conduct almost every type of trial, be it point of care or studies more appropriate for a stand-alone research facility,” said Julie McHugh, CEO of Radiant Research. “We have been looking for a partner that has a shared vision for growth without any sacrifice in quality. In CRA, we have found that partner.”

The combined companies will continue to function under the names of Radiant Research and CRA, but will be looking to integrate and streamline their operations in areas where integration makes sense.

Tempe-based CRA is a provider of a range of research services to pharmaceutical companies and clinical research organizations. As a leading trial management organization, CRA operates from 37 sites across 17 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and efficiently. Founded in 1992, CRA has successfully completed more than 1,800 clinical trials on behalf of its clients. For more information, please visit www.crastudies.com.

clinical research advantage - vaccines

Clinical Research Advantage Earns Vaccine Industry Excellence Award

Tempe-based Clinical Research Advantage, a community-based network of clinical trial sites, has been named Best Clinical Trial Site Network by the World Vaccine Congress. The award was announced at the 2012 Vaccine Industry Excellence Awards in Washington, D.C. on April 11th. The VIE Awards celebrate the leaders, innovators and pioneers in the vaccine industry. Clinical Research Advantage also received second place for Best Clinical Trial Site.

“We are honored to win this prestigious award,” said Mark Hanley, CEO of Clinical Research Advantage. “The key to CRA’s success has been the development of research offices within community physician practices. We take pride in partnering with these established practices to provide rapid, successful enrollment that expedites the process of bringing vaccines to market.”

Casey Orvin, CRA’s Vice President of Business Development was on hand to accept the award in Washington, D.C. “It is with great honor that we accept the award for Best Clinical Trial Site Network. We are grateful to all the pharmaceutical sponsors and CROs who trust our sites and staff, time and time again, to successfully enroll in their vaccine studies. We have been fortunate, for the last several years, to be the leader in providing high quality data and rapidly enrolling sites to the vaccine industry,” said Orvin.

The Vaccine Industry Excellence Award nominees are voted on by an independent judging panel, comprised of senior industry representatives from public health organizations, non-governmental organizations, academic and research institutes, industry experts and affiliate member associations, pharmaceutical, biotech, global consultancies and press affiliates.

For more information on Clinical Research Advantage, visit Clinical Research Advantage’s website at crastudies.com.